Form 4: Mirum Pharma Exec Sells Shares After RSU Vesting

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Summary

• Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, Inc. (MIRM), reported transactions involving company common stock.
• On January 23, 2026, 1,500 restricted stock units (RSUs) vested, resulting in the acquisition of 1,500 shares of common stock.
• Following this acquisition, Howe's beneficial ownership of common stock was 4,542 shares.
• On January 26, 2026, Howe disposed of 842 shares of common stock at a price of $96.192 per share.
• This sale was conducted to cover tax withholding obligations associated with the vesting of the restricted stock units.
• After these reported transactions, Howe beneficially owns 3,700 shares of common stock.
• The restricted stock units vest in three equal annual installments, with 1/3rd vesting on each anniversary of January 23, 2024, until fully vested on the three-year anniversary.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and a tax-related stock sale, which is a standard part of executive compensation and does not indicate a significant positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units and a subsequent tax-related stock sale. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a change in management's confidence or the company's operational performance. The sale of shares to cover taxes is a common practice and not a discretionary sale.

Next Steps

• The remaining restricted stock units will continue to vest annually on January 23, 2024, and its anniversaries, until fully vested on the three-year anniversary of the Vesting Commencement Date.

Key Dates

Recommendation

This Form 4 reports a standard executive compensation event involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are routine and do not typically signal a change in the company's fundamentals or management's outlook, thus warranting a 'hold' recommendation for existing investors.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Executive Compensation, Jolanda Howe